title: Statin use and decline in gait speed in community-dwelling older adults.
abstract: OBJECTIVE
  To examine the association between statin use and objectively assessed decline in gait speed in community-dwelling older adults.
  
  
  METHODS
  Longitudinal cohort study.
  
  
  METHODS
  Health, Aging and Body Composition (Health ABC) Study.
  
  
  METHODS
  Two thousand five participants aged 70-79 at baseline with medication and gait speed data at 1998-99, 1999-2000, 2001-02, and 2002-03.
  
  
  METHODS
  The independent variables were any statin use and their standardized daily doses (low, moderate, high) and lipophilicity. The primary outcome measure was decline in gait speed of 0.1 m/s or more in the following year of statin use. Multivariable generalized estimating equations were used, adjusting for demographic characteristics, health-related behaviors, health status, and access to health care.
  
  
  RESULTS
  Statin use increased from 16.2% in 1998-99 to 25.6% in 2002-03. The overall proportions of those with decline in gait speed of 0.1 m/s or more increased from 22.2% in 1998 to 23.9% in 2003. Statin use was not associated with decline in gait speed of 0.1 m/s or more (adjusted odds ratio (AOR) = 0.90, 95% confidence interval (CI) = 0.77-1.06). Similar nonsignificant trends were also seen with the use of hydrophilic or lipophilic statins. Users of low-dose statins were found to have a 22% lower risk of decline in gait speed than nonusers (AOR = 0.78, 95% CI = 0.61-0.99), which was mainly driven by the results from 1999-2000 follow-up.
  
  
  CONCLUSIONS
  These results suggest that statin use did not increase decline in gait speed in community-dwelling older adults.
authors.affiliation: Center for Pharmaceutical Policy and Prescribing, Health Policy Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
authors.forename: Wei-Hsuan
authors.initials: WH
authors.lastname: Lo-Ciganic
authors.forename: Subashan
authors.initials: S
authors.lastname: Perera
authors.forename: Shelly L
authors.initials: SL
authors.lastname: Gray
authors.forename: Robert M
authors.initials: RM
authors.lastname: Boudreau
authors.forename: Janice C
authors.initials: JC
authors.lastname: Zgibor
authors.forename: Elsa S
authors.initials: ES
authors.lastname: Strotmeyer
authors.forename: Julie M
authors.initials: JM
authors.lastname: Donohue
authors.forename: Clareann H
authors.initials: CH
authors.lastname: Bunker
authors.forename: Anne B
authors.initials: AB
authors.lastname: Newman
authors.forename: Eleanor M
authors.initials: EM
authors.lastname: Simonsick
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Bauer
authors.forename: Suzanne
authors.initials: S
authors.lastname: Satterfield
authors.forename: Paolo
authors.initials: P
authors.lastname: Caserotti
authors.forename: Tamara
authors.initials: T
authors.lastname: Harris
authors.forename: Ronald I
authors.initials: RI
authors.lastname: Shorr
authors.forename: Joseph T
authors.initials: JT
authors.lastname: Hanlon
mesh_terms: D000368:Aged; D001823:Body Composition; D004305:Dose-Response Relationship, Drug; D005260:Female; D005684:Gait / Q000187:drug effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008137:Longitudinal Studies; D008297:Male
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: aged; gait speed; hydroxymethylglutaryl-CoA reductase inhibitors; physical function; statins